Hims & Hers Stock Plummets Amid Regulatory Worries and Debt Concerns
Hims & Hers Health (HIMS) stock is experiencing volatility due to a string of unsettling headlines. Investors are reacting to reports that Visa placed the company in a monitoring program over unusually high credit card disputes in its weight-loss business, as well as an ongoing FTC lawsuit over billing and data practices.
The concerns about regulatory risk and business quality have been compounded by a fresh price target cut from Barclays, which suggests Wall Street is reassessing HIMS's risk profile and future growth. The shares have broken below key moving averages, turning the initial news-driven selloff into a deeper technical rout.
Despite the recent drop, some investors may still take comfort in HIMS's rapid revenue and subscriber growth, which suggests its health platform is gaining traction and could support more predictable sales over time. However, rising debt levels and structurally pressured margins limit how much misstep the business can afford.